Search - tctmd.com

Displaying 301 - 320 of 633

Sort: Relevancy | Date

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Ioanna Kosmidou, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

CENTURY II: A Prospective Randomized Trial of a Bioabsorbable-Polymer Biolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Two-Year Outcomes

Presenter: Spencer B. King III, Jagat Narula, Shigeru Saito

October 12, 2015

Presentation TCT 2015

DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset)

Presenter: Spencer B. King III, Jagat Narula, James B. Hermiller Jr

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Gregg W. Stone, Ron Waksman, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Bernard Chevalier

October 12, 2015

News Industry News

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

October 12, 2015

News Conference News TCT 2015

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

Presentation TCT 2015

I Want to Treat Vulnerable Plaques: Not Today but Tomorrow (From PROSPECT to PROSPECT ABSORB)

Presenter: Gary S. Mintz, Seung-Jung Park, Gregg W. Stone

October 11, 2015

News Industry News

Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015

October 07, 2015

News Industry News

QT Vascular Announces Interim Clinical Trial Results Of Chocolate Touch

October 06, 2015

News Industry News

Medtronic's Valiant® Thoracic Stent Graft System Demonstrates Durability After Five Years

October 05, 2015

News Industry News

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

October 05, 2015

News Industry News

HeartMate 3™ CE Mark Trial Meets Primary Endpoint

September 28, 2015

News Industry News

Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are Maintained After 12 Months

September 28, 2015

News Daily News

Registro OLIVE: ‘Razonables’ Resultados del Tratamiento Endovascular para el Manejo de la ICE a los 3 Años

L.A. McKeown

September 23, 2015

News Daily News

OLIVE登记处：3年时的CLI血管内临床治疗结果“合情合理”

L.A. McKeown

September 23, 2015

News Daily News

OLIVE Registry: Endovascular Therapy Outcomes for CLI ‘Reasonable’ at 3 Years

L.A. McKeown

September 23, 2015

Presentation

3-year Outcomes of the OLIVE Registry: A Prospective Multicenter Study of CLI

Presenter: O. Iida

September 22, 2015

News Daily News

Un Estudio de Registro Vincula las PCI por OTC a una Mejor Supervivencia vs. Tratamiento Médico y CABG

September 17, 2015

Advertisement

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

CENTURY II: A Prospective Randomized Trial of a Bioabsorbable-Polymer Biolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Two-Year Outcomes

DAPT: A Prospective, Double-blind, Placebo-controlled Randomized Trial of 1-year Versus 2.5 Years of Dual Anti-platelet Therapy (Everolimus-Eluting Stent-Treated Subset)

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

I Want to Treat Vulnerable Plaques: Not Today but Tomorrow (From PROSPECT to PROSPECT ABSORB)

Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015

QT Vascular Announces Interim Clinical Trial Results Of Chocolate Touch

Medtronic's Valiant® Thoracic Stent Graft System Demonstrates Durability After Five Years

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

HeartMate 3™ CE Mark Trial Meets Primary Endpoint

Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are Maintained After 12 Months

Registro OLIVE: ‘Razonables’ Resultados del Tratamiento Endovascular para el Manejo de la ICE a los 3 Años

OLIVE登记处：3年时的CLI血管内临床治疗结果“合情合理”

OLIVE Registry: Endovascular Therapy Outcomes for CLI ‘Reasonable’ at 3 Years

3-year Outcomes of the OLIVE Registry: A Prospective Multicenter Study of CLI

Un Estudio de Registro Vincula las PCI por OTC a una Mejor Supervivencia vs. Tratamiento Médico y CABG

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content